GlassScriptPhysician profile
Jennifer Daif Parker
NPI 1447477633
$3,649.29
in general payments reported to CMS, 2019-2025
26 companies · $397 in 2025
The $397 reported for 2025 was more than what 75% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $663 · 2020: $241 · 2021: $412 · 2022: $744 · 2023: $688 · 2024: $504 · 2025: $397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,561 · Education: $19.27 · Gift: $9.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,560.92 |
| Education | $19.27 |
| Gift | $9.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,564.61 | 2019-2025 | Evenity, Prolia, Prolia |
| Abbvie INC. | $374.15 | 2019-2025 | Oriahnn, Lo Loestrin Fe, Orilissa |
| Intuitive Surgical, INC. | $210.14 | 2019-2023 | Da Vinci Surgical System |
| Gynesonics, INC. | $190.71 | 2022 | |
| Acera Surgical, INC. | $151.56 | 2025 | Restrata Wound Matrix |
| Mayne Pharma Commercial LLC | $150.88 | 2021-2025 | |
| Novo Nordisk INC | $131.90 | 2023 | Wegovy |
| Pfizer INC. | $126.90 | 2019-2024 | |
| Hologic Sales and Service, LLC | $96.55 | 2021-2025 | Aptima, Thinprep 2000 Processor |
| Radiometer America, INC | $80.58 | 2024 | |
| Exeltis, USA INC. | $79.81 | 2019-2024 | Slynd |
| Ge Healthcare | $63.89 | 2021-2024 | |
| Therapeuticsmd, INC. | $63.14 | 2019-2021 | |
| Lsi Solutions INC | $51.32 | 2022 | |
| Duchesnay USA Incorporated | $45.70 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $42.28 | 2024 | Veozah |
| Sumitomo Pharma America, INC. | $38.45 | 2023-2025 | Myfembree |
| Avion Pharmaceuticals | $37.82 | 2019-2021 | |
| Mylan Pharmaceuticals INC. | $35.97 | 2022 | |
| Millicent US INC | $35.09 | 2024-2025 | Femlyv, Femring, Intrarosa |
| Organon LLC | $24.49 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.03 | 2025 | |
| Biogen, INC. | $14.04 | 2025 | Zurzuvae |
| Ascend Therapeutics US, LLC | $11.14 | 2021 | |
| Lupin INC. | $11.14 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Parker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.